Repare Therapeutics Inc. (RPTX)

3,5000 -0,1400 (-3,85%) Al cierre: 04:00PM EDT

Repare Therapeutics Inc.

7171 Frederick-Banting, Building 2
Suite 270 St-Laurent
Montréal, QC H4S 1Z9
Canada
857 412 7018
https://www.reparerx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 179

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Lloyd Mitchell Segal	President, CEO & Director	932,18k	N/A	1964
Mr. Steve Forte	Executive VP & CFO	632k	N/A	1979
Dr. Maria Koehler M.D., Ph.D.	Executive VP & Chief Medical Officer	693,28k	N/A	1957
Dr. Daniel Durocher Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Frank Sicheri Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Agnel Sfeir Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Michael Zinda Ph.D.	Executive VP & Chief Scientific Officer	641,53k	N/A	1971
Mr. Daniel Belanger	Executive Vice President of Human Resource	N/A	N/A	N/A
Mr. Cameron Black	Executive Vice President of Discovery	N/A	N/A	N/A
Dr. Kim A. Seth Ph.D.	Executive VP & Chief Business Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Gobierno corporativo

El ISS Governance QualityScore de Repare Therapeutics Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.